Jeffrey V Lazarus

NFL Legend Dan Marino Talks About His MASH, Liver Disease Diagnosis NFL Hall of Fame quarterback Dan Marino has revealed his metabolic dysfunction-associated steatohepatitis or MASH diagnosis. Here's what this liver disease is.

🏈🩺 #CUNYSPH Prof. Bruce Y Lee explores NFL legend Dan Marino’s MASH (metabolic dysfunction–associated steatohepatitis) diagnosis in Forbes featuring insights from Prof. Jeffrey V Lazarus on the prevalence and public health risks of liver disease. cunysph.me/48CD1Vx

Chronic diseases are squeezing economies. Leaders don’t have much of a plan. The United Nations General Assembly is expected to sign off on a watered-down commitment to tackle noncommunicable diseases.

A new Politico piece on chronic diseases quotes #CUNYSPH Prof. Jeffrey V Lazarus on how food environments shape health more than “individual choice”.

💬 “What are the options, what’s available, do you even have the ability to purchase healthy foods?”

Read more: cunysph.me/4gPQMT7

YouTube video by CUNY SPH Shaping the Spanish National Health System with a Global Health Perspective, Sept 18, 2025

Tx for sharing. My question for Spain's secretary of health comes at 1 hour 9 min. It's about the commercial determinants of health and how Spain can reconcile its work to reduce NCDs while fomenting the sale of alcohol.
youtu.be/p3wYHX8I5eg?...
Our call to action:
www.thelancet.com/journals/lan...

A view of Wiston House. Text reads: New blog - 80 years of Wilton Park: Professor Jeffrey V Lazarus

💬 'Wilton Park has shown to be a powerful outlet to reach world leaders and shape strategic health discussions.'

In our latest blog, @jvlazarus.bsky.social explains how his partnership with Wilton Park has delivered policy impact.

#WiltonPark80

🔗 wiltonpark.org.uk/idea/80-year...

YouTube video by LIVERAIM LIVERAIM webinar #3: A Deep Dive into Steatotic Liver Disease Policy and Regulatory Processes

🚨 Don't miss the third webinar of the #LIVERAIM series!

📹 youtube.com/watch?v=qdM_...

#SLDthinktank

@jvlazarus.bsky.social @ihieurope.bsky.social @easlnews.bsky.social @majathiele.bsky.social @salvatore-piano.bsky.social @aleksanderkrag.bsky.social

😶Liver disease is often suffered in silence.
Stigma and shame block care.

💡It’s a chronic illness, not consequence of bad choices.

🩺Everyone deserves support.
At #LIVERAIM, we’re breaking the silence.

#EndTheStigma #LiverHealthMatters #HealthEquity

@ihieurope.bsky.social @easlnews.bsky.social

The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality Liver diseases have become a major health threat across Europe, and the face of European hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral hepatitis B, the i...

Read about stigma in the EASL-Lancet liver health commission:
www.thelancet.com/journals/lan...
#LiverSky

The People-First Liver Charter - Nature Medicine Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived — a shift that begins...

Happy to support and endorse the People First Liver Charter in
‪‪@natmed.nature.com‬‬ www.nature.com/articles/s41...

We've always taken a sensitive approach to the language used in our journal, and will continue to do so. See this Editorial www.nature.com/articles/s41...

The People-First Liver Charter - Nature Medicine Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived — a shift that begins...

The People-First Liver Charter - opportunities for improving awareness, tackling stigma, building accessible care pathways, maintaining linkage to treatment/monitoring, & reducing health inequities.
🧪
Led by @jvlazarus.bsky.social
#NoHep #MedSky #HepSky #LiverSky
www.nature.com/articles/s41...

The People-First Liver Charter - Nature Medicine Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived — a shift that begins...

At the Global Think-tank on Steatotic Liver Disease, we launched the People-First Liver Charter
www.nature.com/articles/s41...

+ A call for doubling the diagnostic rate of at-risk MASH
www.thelancet.com/journals/lan...
#SLDthinktank #InMotionTogether #LiverSky

Congratulations to @jvlazarus.bsky.social on receiving the Eugene T. Davidson Public Service Award from the American Association of Clinical Endocrinology!

This award recognises exceptional contributions to clinical excellence, research, public health, and community engagement in #endocrinology.

Here we are in Spanish talking liver health. #WorldLiverDay

Food inequity and insecurity and MASLD: burden, challenges, and interventions - Nature Reviews Gastroenterology & Hepatology Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence is increasing worldwide, and a crucial risk factor is food insecurity. This Review provides an extensive overview of food in...

Food inequity and insecurity and MASLD: burden, challenges, and interventions
www.nature.com/articles/s41...
@natrevgastrohep.nature.com
is a major theme of #WorldLiverDay:
worldliverday.org/food-is-medi...
#LiverSky @easlnews.bsky.social #HealthyLiversHealthyLives

We support the @ncdalliance priorities for the 4th United Nations High-level Meeting on NCDs Political Declaration sldthinktank.com/un-hlm-2025-... and further call on UN Member States to develop #BestBuy interventions to address SLD:
www.thelancet.com/journals/lan...

#LiverSky #SLDthinktank

Read about Chronic Liver Disease, MASLD/MASH, and the Global NCD Agenda in the context of the United Nations General Assembly High-level Meeting on NCDs this Sept. We need to take action every day and not just on #WorldLiverDay!
sldthinktank.com/un-hlm-2025-...
#liversky #SLDthinktank

🌎Did you know 1 in 3 adults worldwide has #MASLD?
It’s tied to obesity, diabetes & high cholesterol, it can lead to fibrosis and cancer.
This #WorldLiverDay remember: #FoodIsMedicine!
💪Let's make #liverhealth a priority
@easlnews.bsky.social @ihieurope.bsky.social @europeliver.bsky.social

"Food is Medicine" -But for whom? The accessibility problem in nutrition and liver health:
worldliverday.org/food-is-medi...
#WorldLiverDay #SLDthinktank #LiverSky
@easlnews.bsky.social @ebtapper.bsky.social @aleksanderkrag.bsky.social @debbieshawcross.bsky.social @melinamanolas.bsky.social

Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden Data on cause-specific mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We aimed to determine the rate and risk of death from different causes in patients wit...

New paper from us in @jhepatology.bsky.social: www.journal-of-hepatology.eu/article/S016...
Causes of death in >13,000 persons with #MASLD - check it out #liversky. So proud of co-senior author Axel Wester and first author medical student Gabriel Issa for the work!

It's a must-read #LiverSky

YouTube video by LIVERAIM Early diagnosis of Chronic Liver Disease - What does it means for patients?

❓Did you miss the second #LIVERAIM webinar?

Check out our Youtube channel and discover what an #earlydiagnosis of #chronicliverdisease truly means for patients!

🎥 www.youtube.com/watch?v=jmw5...

@easlnews.bsky.social @ihieurope.bsky.social @europeliver.bsky.social

Metabolic dysfunction-associated steatotic liver disease encompasses a spectrum from metabolic dysfunction-associated steatotic liver or isolated hepatic steatosis through to metabolic dysfunction-associated steatohepatitis (#MASH). #MASLD
https://www.nature.c...

New Nature disease primer on #MASLD out now. MASLD affects 1 in 3 adults, yet it’s still underrecognized beyond #hepatology. That’s why our multidisciplinary team collaborated to cover epidemiology, diagnosis, treatment & prevention

🔗https://www.nature.com/articles/s41572-025-00599-1

#LiverSky

In a related topic, more about MASLD in an amazing Nature Reviews Disease Primers article just published:

🔗 nature.com/articles/s41...

@jvlazarus.bsky.social

The second @liveraim.bsky.social webinar is now underway...! You can view the first webinar on demand here:
www.liveraim.eu/webinars/
#LiverSky LIVERAIM is working to improve early detection of chronic liver disease through the development of a new biomarker-based personalized risk calculator.

📌Tomorrow is the day: don't miss the 2nd #LIVERAIM webinar!

✒️Register now! tinyurl.com/bdhyjv8e

@europeliver.bsky.social @easlnews.bsky.social @jvlazarus.bsky.social @aleksanderkrag.bsky.social @mkdmilan.bsky.social @majathiele.bsky.social @worldhepalliance.bsky.social

WHO "emphasizes the value of an integrated approach to HIV", drawing on our important evidence:
"Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (#INTEAFRICA): a pragmatic cluster-randomised, controlled trial"
www.thelancet.com/journals/lan... @gavinyamey.bsky.social

⌛️4 day left!
Join 2nd #LIVERAIM webinar and learn what patients really think about #earlydiagnosis: the hopes, the fears, and the reality!

🗓️3 March 17:30-18:10 CET

👉Register now tinyurl.com/bdhyjv8e

@europeliver.bsky.social @easlnews.bsky.social @jvlazarus.bsky.social @aleksanderkrag.bsky.social

📣 The second #LIVERAIM webinar is on the way!

Early diagnosis of chronic liver disease - What does it mean for patients?

🗓️ 3 March 17:30-18:10 CET

🔗 Register now! tinyurl.com/4j97xhp9

#earlydiagnosis #changingtheparadigm

@easlnews.bsky.social @aleksanderkrag.bsky.social @jvlazarus.bsky.social

Welcome immigrants from X interested in science to the friendlier skies of @bsky.app, as documented by a new @nature.com survey (but you already knew that 😉)
"Bluesky is much better for science. There is much less toxicity, misinformation, and distractions."
www.nature.com/articles/d41...

The 🌎 burden of #MASH is staggering: 5.3% of adults face higher risks of cirrhosis, liver cancer & other complications as fibrosis progresses.
our latest study on MAESTRO-NASH resmetirom data & its real-world implications post-FDA approval www.nature.com/articles/s44... #SLDsummit